Enlivex Therapeutics Ltd. (TLV:ENLV)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
384.40
+7.70 (2.04%)
Feb 20, 2025, 5:24 PM IDT
-68.87%
Market Cap 78.38M
Revenue (ttm) n/a
Net Income (ttm) -70.38M
Shares Out n/a
EPS (ttm) -3.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 27,865
Average Volume 37,375
Open 376.70
Previous Close 376.70
Day's Range 375.00 - 390.00
52-Week Range 350.00 - 1,600.00
Beta 0.99
RSI 40.47
Earnings Date Mar 28, 2025

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Oren Hershkovitz
Country Israel
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol ENLV
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.